Powered by
BreastCancerTrials.org
  • ALL TRIALS

  • Register to create a profile
    Enter your treatment history for more accurate matching.

    MY PROFILE
  • MY FAVORITES

You have matched to trials (Last updated: July 01, 2022) Back to Metastatic Trial Search

and or
   Reset
Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
➤
All Trials▶ All Phases▶ Sorted by zip code: 94107▶Distance: All U.S.    Filter by Trial TypeFilter by Mutations
Close
Treatment

Brain Mets required

Brain: Leptomeningeal Mets required

BRCA1/2 (inherited)

Chemotherapy

Hormone Therapy

Radiation Oncology

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Genetics/Family History

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Support/Education

Surveys/Interviews/Registries

Close

AKT

ALK

AR

BARD1

BRCA1/2 (tumor)

BRIP1

CD205

CD70

CHEK2 or CHEK1

ESR1

FGFR

HER2/ERBB2

HLA

MET or C-Met

NTRK

PALB2

PIK3CA or PI3K

PTEN

RAD51

RAF (including BRAF)

RAS (KRAS or NRAS)

RB

ROS1

TP53

No travel requiredTrials coming soon to MTSAdditional metastatic cancer trials

1

NEAREST SITE: 0 miles
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, CA

VISITS: 3 visits a month, ongoing

PHASE: II

NCT ID: NCT04090398

Paclitaxel Alone or With Radium-223 Dichloride For Metastatic HER2 Negative Breast Cancer With Bone Metastases

Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer Scientific Title

Purpose
To study the anti-cancer activity and effects (good and bad) of giving radium-223 dichloride (a type of radiation therapy given by IV) in combination with paclitaxel (Taxol®).
Who is this for?
People with metastatic (stage IV), HER2 negative (HER2-) breast cancer that has spread to the bone and who have not received more than three lines of chemotherapy for metastatic disease.    Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly (3 weeks on, 1 week off), ongoing</li> <li class="seamTextUnorderedListItem">Radium 223 dichloride (Xofigo®), by IV, once a month, for 6 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly (3 weeks on, 1 week off), ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®) is a chemotherapy routinely used to treat metastatic breast cancer.</li> <li class="seamTextUnorderedListItem">Radium-223 dichloride (Xofigo®) is a radiation therapy given by IV. It works by killing cancer cells and may reduce the pain caused by <span class="highlight">bone</span> metastases. </li> <li class="seamTextUnorderedListItem">Radium-223 dichloride (Xofigo®) is approved to treat metastatic prostate cancer that has spread to the <span class="highlight">bones</span>. Its use in breast cancer is considered experimental.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04090398' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/oral-vs-iv-paclitaxel-for-mbc' target='_blank'>Breastcancer.org: Is Oral Paclitaxel Better Than IV Paclitaxel for Metastatic Breast Cancer?</a> </li><li class='seamTextUnorderedListItem'><a href='http://chemocare.com/chemotherapy/drug-info/radium-223-dichloride.aspx' target='_blank'>Chemocare: Radium 223 Dichloride</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Radium-223' target='_blank'>Wikipedia: Radium-223</a> </li><li class='seamTextUnorderedListItem'><a href='http://mbcn.org/bone-mets/' target='_blank'>Metastatic Breast Cancer Network: Bone Mets</a> </li></ul>
See more
2

NEAREST SITE: 0 miles
Dana-Farber Cancer Institute
Boston, MA

VISITS: 2 visits over 4 months

PHASE: II

NCT ID: NCT04316117

Using PET/CT Scans to See How Breast Cancer That Has Spread to the Bones is Responding to Therapy

FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE Scientific Title

Purpose
To study if PET/CT scans with a FDG tracer find tumors missed by standard of care imaging and can see how breast cancer tumors that have spread to the bones are responding to therapy.
Who is this for?
People with stage IV (metastatic) breast cancer that has spread to their bones and who have not received more than 3 chemotherapies for metastatic disease.    Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FDG tracer, by IV, followed by PET/CT scan, 2 times (1 scan before treatment, 1 scan 3 months after starting treatment)</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">This imaging trial will use a tracer called FDG (fluorodeoxyglucose). </li> <li class="seamTextUnorderedListItem">FDG produces color-coded images that show normal and cancerous tissue.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04316117' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ecog-acrin.org/clinical-trials/ea1183-educational-materials' target='_blank'>ECOG-ACRIN Study Information Page: FEATURE</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/tests/pet-ct-scan' target='_blank'>Cancer Research UK: PET-CT Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.docpanel.com/blog/post/understanding-your-fdg-pet-scan' target='_blank'>Docpanel: Understanding Your FDG PET Scan</a> </li></ul>
See more
3

NEAREST SITE: 0 miles
Maine Medical Center-Bramhall Campus
Portland, ME

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT03691493

Radiation Therapy, Palbociclib & Hormone Therapy for Breast Cancer Related Bone Metastases

A Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer Patients Scientific Title

Purpose
To study the effects (good and bad) of using radiation therapy along with the targeted therapy palbociclib (Ibrance®) and hormone therapy.
Who is this for?
People with metastatic (stage IV) hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer that has spread to the bone.    Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy, daily, for 5-10 days</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily, for 3 out of every 4 weeks</li> <li class="seamTextUnorderedListItem">Your doctor's choice of hormone therapy: letrozole, anastrozole, exemestane, tamoxifen, or fulvestrant</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. </li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®) is a type of targeted therapy called a CDK 4/6 inhibitor. It is used along with a hormone therapy to treat metastatic breast cancer. </li> <li class="seamTextUnorderedListItem">The hormone therapies used along with Ibrance are fulvestrant (Faslodex®), letrozole (Femara®), anastrozole (Arimidex®), exemestane (Aromasin®) and tamoxifen.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD).</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03691493' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://cancerres.aacrjournals.org/content/79/4_Supplement/PD8-12' target='_blank'>AACR Cancer Research Abstract: Safety and efficacy of palbociclib and radiotherapy in MBC</a> </li></ul>
See more

My Profile

Create a complete profile for more accurate trial matching. You can edit at any time.

BREAST CANCER DIAGNOSIS

Biomarkers Add
Placeholder
Tumor Type Add
Placeholder
Evidence of Disease Add
Placeholder
Measurable Disease Add
Placeholder
Date of MBC Diagnosis Add
Placeholder

CONFIRM DELETING ROW

Are you sure you wish to delete this?


CONFIRM DELETING USER

Are you sure?


CONFIRM PROFILE CHANGES

The changes you have made to the profile will be saved.


SAVE PROFILE CHANGES

Do you want to save all the changes made before logout?


BIOMARKERS

What is your breast cancer type based on your latest biopsy?

Select all that apply

Estrogen receptor (ER)
Progesterone receptor (PR)
HER2/neu (HER2)
BRCA1/2 (inherited)
Androgen receptor (AR)
PD-L1
PIK3CA

TUMOR TYPE

Has your tumor been described as any of the following?


EVIDENCE OF DISEASE

Where do you currently have evidence of disease?

Eyeball, socket


What is the current status of your brain mets?

The two innermost layers of tissue that cover the brain and spinal cord

Peritoneum, omentum

Esophagus, stomach, small intestine, large intestine

Ovaries, uterus, fallopian tubes

Please select the current status of your brain mets


MEASURABLE DISEASE

Are your tumors measurable?

For accurate matching, we suggest you consult with your provider.


DATE OF MBC DIAGNOSIS

What was the date of your metastatic diagnosis?

Invalid date


STAGE OF FIRST DIAGNOSIS

Have you ever received treatment for metastatic (Stage IV) breast cancer?


DEMOGRAPHICS

Biological Sex Add
Placeholder
Birth Year Add
Placeholder
Zipcode Add
Placeholder
Race Add
Placeholder
Latino/a or Hispanic Add
Placeholder

BIOLOGICAL SEX

What is your biological sex?


What is your current menopausal status?


BIRTH YEAR

What is your birth year?

Invalid birth year


ZIPCODE

What is your zipcode?

Invalid zipcode


RACE

What is your race?


Ethnicity

Do you identify as Latino/a or Hispanic?


TREATMENT HISTORY

Treatment received for metastatic breast cancer?

Note: Please be sure to enter medication, radiation, or surgery for accurate results. Otherwise, select "Skip this question" to view trials regardless of treatment received for metastatic breast cancer.


ADD METASTATIC MEDICATION
Placeholder

Is this treatment a part of a clinical trial?


Are you currently on this treatment?


Did your cancer progress on this treatment?




SHOW RADIATION TREATMENT SAVED
Placeholder

RADIATION TREATMENT (Metastatic)
Placeholder

RADIATION SITES


SHOW SURGERY SAVED
Placeholder

SURGERY
Placeholder
SURGERY / PROCEDURES (select all that apply)

ADD ALL MEDICATIONS RECEIVED FOR EARLY STAGE BREAST CANCER
SELECT BRAND NAME GENERIC NAME CATEGORY

ADD ALL MEDICATIONS RECEIVED TOGETHER
SELECT BRAND NAME GENERIC NAME CATEGORY

ADD ALL MEDICATIONS RECEIVED TOGETHER
SELECT BRAND NAME GENERIC NAME CATEGORY

Medication received for early stage breast cancer?

Note: Please be sure to enter medication(s) for accurate results. Otherwise, select "Skip this question" to view trials regardless of medication received for early stage breast cancer.


My Favorites

ADDITIONAL INFO